John S Welch

List of Publications by Year
in descending order

87	19,632	186265	102487
papers	citations	28 h-index	66 g-index

89	89	89	27094
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia. New England Journal of Medicine, 2013, 368, 2059-2074.	27.0	4,139
2	Mutational landscape and significance across 12 major cancer types. Nature, 2013, 502, 333-339.	27.8	3,695
3	Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature, 2012, 481, 506-510.	27.8	1,795
4	DNMT3AMutations in Acute Myeloid Leukemia. New England Journal of Medicine, 2010, 363, 2424-2433.	27.0	1,777
5	Age-related mutations associated with clonal hematopoietic expansion and malignancies. Nature Medicine, 2014, 20, 1472-1478.	30.7	1,533
6	The Origin and Evolution of Mutations in Acute Myeloid Leukemia. Cell, 2012, 150, 264-278.	28.9	1,365
7	Interleukin-4-dependent production of PPAR-Î³ ligands in macrophages by 12/15-lipoxygenase. Nature, 1999, 400, 378-382.	27.8	822
8	Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature, 2015, 518, 552-555.	27.8	685
9	TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. New England Journal of Medicine, 2016, 375, 2023-2036.	27.0	663
10	SciClone: Inferring Clonal Architecture and Tracking the Spatial and Temporal Patterns of Tumor Evolution. PLoS Computational Biology, 2014, 10, e1003665.	3.2	400
11	Immune Escape of Relapsed AML Cells after Allogeneic Transplantation. New England Journal of Medicine, 2018, 379, 2330-2341.	27.0	322
12	Association Between Mutation Clearance After Induction Therapy and Outcomes in Acute Myeloid Leukemia. JAMA - Journal of the American Medical Association, 2015, 314, 811.	7.4	302
13	Patterns and functional implications of rare germline variants across 12 cancer types. Nature Communications, 2015, 6, 10086.	12.8	243
14	Use of Whole-Genome Sequencing to Diagnose a Cryptic Fusion Oncogene. JAMA - Journal of the American Medical Association, 2011, 305, 1577.	7.4	233
15	Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood, 2015, 126, 2484-2490.	1.4	207
16	10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematology,the, 2020, 7, e724-e736.	4.6	201
17	CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression. Cell, 2017, 168, 801-816.e13.	28.9	177
18	Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential. Nature Communications, 2018, 9, 455.	12.8	150

#	Article	IF	Citations
19	Rapid expansion of preexisting nonleukemic hematopoietic clones frequently follows induction therapy for de novo AML. Blood, 2016, 127, 893-897.	1.4	94
20	Mutation Clearance after Transplantation for Myelodysplastic Syndrome. New England Journal of Medicine, 2018, 379, 1028-1041.	27.0	93
21	Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression. Journal of Clinical Investigation, 2011, 121, 1445-1455.	8.2	91
22	Acute Myeloid Leukemia: The Good, the Bad, and the Ugly. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 555-573.	3.8	71
23	Retinoic Acid Receptors in Acute Myeloid Leukemia Therapy. Cancers, 2019, 11, 1915.	3.7	49
24	Decitabine inTP53-Mutated AML. New England Journal of Medicine, 2017, 376, 796-798.	27.0	45
25	Patterns of mutations in TP53 mutated AML. Best Practice and Research in Clinical Haematology, 2018, 31, 379-383.	1.7	43
26	Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: A phase I study. American Journal of Hematology, 2011, 86, 796-800.	4.1	39
27	Genomics of AML: Clinical Applications of Next-Generation Sequencing. Hematology American Society of Hematology Education Program, 2011, 2011, 30-35.	2.5	37
28	PML-RARA can increase hematopoietic self-renewal without causing a myeloproliferative disease in mice. Journal of Clinical Investigation, 2011, 121, 1636-1645.	8.2	35
29	A case of acute myeloid leukemia with promyelocytic features characterized by expression of a novel RARG-CPSF6 fusion. Blood Advances, 2018, 2, 1295-1299.	5.2	25
30	Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10â€day decitabine regimen. Cancer Medicine, 2017, 6, 2814-2821.	2.8	21
31	TP53 immunohistochemistry correlates with TP53 mutation status and clearance in decitabine-treated patients with myeloid malignancies. Haematologica, 2019, 104, e345-e348.	3.5	21
32	Interim Analysis of Phase II Study of Venetoclax with 10-Day Decitabine (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood, 2018, 132, 286-286.	1.4	19
33	Endogenous retinoid X receptor ligands in mouse hematopoietic cells. Science Signaling, 2017, 10, .	3.6	18
34	Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells. Leukemia, 2022, 36, 935-945.	7.2	18
35	Rara haploinsufficiency modestly influences the phenotype of acute promyelocytic leukemia in mice. Blood, 2011, 117, 2460-2468.	1.4	17
36	Mutation Position Within Evolutionary Subclonal Architecture in AML. Seminars in Hematology, 2014, 51, 273-281.	3.4	17

#	Article	IF	Citations
37	Integrative omics analyses broaden treatment targets in human cancer. Genome Medicine, 2018, 10, 60.	8.2	17
38	A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML. American Journal of Hematology, 2014, 89, E103-8.	4.1	15
39	Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial. Blood, 2019, 134, 2637-2637.	1.4	15
40	A protease-resistant PML-RARÎ± has increased leukemogenic potential in a murine model of acute promyelocytic leukemia. Blood, 2010, 116, 3604-3610.	1.4	12
41	Pathways of retinoid synthesis in mouse macrophages and bone marrow cells. Journal of Leukocyte Biology, 2016, 99, 797-810.	3.3	12
42	Smc3 is required for mouse embryonic and adult hematopoiesis. Experimental Hematology, 2019, 70, 70-84.e6.	0.4	12
43	Endogenous and combination retinoids are active in myelomonocytic leukemias. Haematologica, 2021, 106, 1008-1021.	3.5	11
44	Convergent Clonal Evolution of Signaling Gene Mutations Is a Hallmark of Myelodysplastic Syndrome Progression. Blood Cancer Discovery, 2022, 3, 330-345.	5.0	10
45	Outcomes in Molecular Subgroups and Resistance Patterns with Ten-Day Decitabine and Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia. Blood, 2019, 134, 645-645.	1.4	9
46	Mutations In the DNA Methyltransferase Gene DNMT3A Are Highly Recurrent In Patients with Intermediate Risk Acute Myeloid Leukemia, and Predict Poor Outcomes. Blood, 2010, 116, 99-99.	1.4	9
47	Recurrent Transcriptional Responses in AML and MDS patients Treated with Decitabine. Experimental Hematology, 2022, , .	0.4	5
48	Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia. JCO Precision Oncology, 2021, 5, 191-203.	3.0	4
49	Clonal Evolution of Acute Myeloid Leukemia Following Allogeneic Stem Cell Transplantation. Blood, 2016, 128, 1528-1528.	1.4	4
50	Hand-foot syndrome following decitabine. Annals of Hematology, 2016, 95, 535-536.	1.8	3
51	RXRA DT448/9PP generates a dominant active variant capable of inducing maturation in acute myeloid leukemia cells. Haematologica, 2022, 107, 417-426.	3.5	3
52	Outcomes of Relapsed or Refractory Acute Myeloid Leukemia after Frontline Hypomethylating Agent with Venetoclax Regimens. Blood, 2019, 134, 738-738.	1.4	3
53	Dynamic Changes in the Clonal Structure of MDS and AML in Response to Epigenetic Therapy. Blood, 2015, 126, 610-610.	1.4	3
54	Pathways of Retinoid Synthesis in Mouse Bone Marrow-Derived Macrophages and Hematopoietic Progenitors. Blood, 2015, 126, 1009-1009.	1.4	3

#	Article	IF	Citations
55	Serendipity: decitabine monotherapy induced complete molecular response in a 77-year-old patient with acute promyelocytic leukemia. Haematologica, 2019, 104, e170-e173.	3.5	2
56	A Phase I/II Trial of Intravenous Azacitidine for Acute Gvhd Prophylaxis in Patients Undergoing Matched Unrelated Stem Cell Transplantation: Phase I Results. Blood, 2015, 126, 1935-1935.	1.4	2
57	Expanding dasatinib beyond KIT in acute myeloid leukemia. Haematologica, 2020, 105, 2708-2710.	3.5	2
58	Modeling, Synthesis, and Biological Evaluation of Potential Retinoid-X-Receptor (RXR) Selective Agonists: Analogs of 4-[1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahyro-2-naphthyl)ethynyl]benzoic Acid (Bexarotene) and 6-(Ethyl(4-isobutoxy-3-isopropylphenyl)amino)nicotinic Acid (NEt-4IB). International Journal of Molecular Sciences, 2021, 22, 12371.	4.1	2
59	Decitabine salvage for <i>TP53</i>-mutated, relapsed/refractory acute myeloid leukemia after cytotoxic induction therapy. Haematologica, 2022, 107, 1709-1713.	3.5	2
60	TP53 and the star-crossed lovers MDS and AML. Blood, 2022, 139, 2265-2266.	1.4	2
61	Lenalidomide results in a durable complete remission in acute myeloid leukemia accompanied by persistence of somatic mutations and a T-cell infiltrate in the bone marrow. Haematologica, 2018, 103, e270-e273.	3.5	1
62	Exome analysis of treatmentâ€related <scp>AML</scp> after <scp>APL</scp> suggests secondary evolution. British Journal of Haematology, 2019, 185, 984-987.	2.5	1
63	Cytokine exposure mediates transcriptional activation of the orphan nuclear receptor Nur77 in hematopoietic cells. Journal of Biological Chemistry, 2021, 297, 101240.	3.4	1
64	Expression of PML-RARÎ± by the Murine PML Locus Leads to Myeloid Self-Renewal, Clonal Expansion and Morphologic Promyelocytic Leukemia.. Blood, 2008, 112, 932-932.	1.4	1
65	A Phase I Dose-Escalation Study of Combination Decitabine, Arsenic Trioxide and Ascorbic Acid In Patients with MDS and AML. Blood, 2010, 116, 2148-2148.	1.4	1
66	Complete Sequencing and Comparison of 12 Normal Karyotype M1 AML Genomes with 12 t(15;17) Positive M3-APL Genomes. Blood, 2011, 118, 404-404.	1.4	1
67	Dynamic Changes in Clonal Clearance with Decitabine Therapy in AML and MDS Patients. Blood, 2015, 126, 689-689.	1.4	1
68	Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia and Myelodysplastic Syndrome: Updated Results of a Phase II Trial. Blood, 2021, 138, 1270-1270.	1.4	1
69	Solid, Low-Attenuation Splenic Lesions on Computed Tomography in Patients With Indolent Lymphoma Often Signal Transformation: A Series of Ten Patients. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 452-454.	0.4	0
70	A Protease-Resistant PML-RARÎ± Has Increased Leukemogenic Potential in a Murine Model of Acute Promyelocytic Leukemia (APL).. Blood, 2008, 112, 930-930.	1.4	0
71	Cladribine in the Treatment of Acute Myeloid Leukemia. Blood, 2008, 112, 4032-4032.	1.4	0
72	The Effect of Rara Haploinsufficiency in a Mouse Model of Acute Promyelocytic Leukemia.. Blood, 2009, 114, 3475-3475.	1.4	0

#	Article	IF	Citations
73	Resolution of a Clinical Dilemma with Whole Genome Sequencing, and Discovery of a New Mechanism for Generating PML-Rara: Insertional Fusion. Blood, 2010, 116, 2755-2755.	1.4	0
74	Deep Digital Sequencing Identifies an AML Subclone with Enhanced in Vitro and in Vivo Growth Properties Associated with Disease Relapse. Blood, 2012, 120, 407-407.	1.4	0
75	A Phase I Dose Escalation Study Of Oral Bexarotene In Combination With Intravenous Decitabine In Patients With AML. Blood, 2013, 122, 3931-3931.	1.4	0
76	Plerixafor, G-CSF and Azacitidine For The Treatment Of MDS: Results Of a Phase I Trial. Blood, 2013, 122, 2816-2816.	1.4	0
77	Natural Ligands for Rxra, but Not Rara, Are Observed in Mouse Bone Marrow Cells, and Are Augmented in Response to 5FU and GCSF. Blood, 2014, 124, 4339-4339.	1.4	0
78	Non-Malignant Oligoclonal Hematopoiesis Commonly Follows Cytoreductive Chemotherapy in Adult De Novo AML Patients. Blood, 2015, 126, 686-686.	1.4	0
79	Smc3 Haploinsufficiency and Smc3 Deletion Alter Hematopoiesis In Vivo. Blood, 2016, 128, 2903-2903.	1.4	0
80	Improving Risk Assessment of AML with a Precision Genomic Strategy to Assess Mutation Clearance. Blood, 2018, 132, 5277-5277.	1.4	0
81	Endogenous Retinoid X Receptor Ligands Act As Tumor Suppressors in MLL-AF9 Mouse Leukemia. Blood, 2019, 134, 2677-2677.	1.4	0
82	Whole Genome Bisulfite Sequencing of 63 Primary AML Samples Identifies a Unique DNA Hypermethylation Signature for Mutant IDH1/2 Cases That Is Different from That of TET2 Mutant AML. Blood, 2019, 134, 3755-3755.	1.4	0
83	Adverse Outcomes in Acute Myeloid Leukemia Are Associated with Tumor Cell-Mediated Immunosuppression. Blood, 2021, 138, 800-800.	1.4	0
84	Phase II Trial of Ten-Day Decitabine with Venetoclax (DEC10-VEN) in Acute Myeloid Leukemia: Updated Outcomes in Genomic Subgroups. Blood, 2021, 138, 694-694.	1.4	0
85	Molecular Profiling of Decitabine Response in MDS and AML Patients. Blood, 2020, 136, 40-40.	1.4	0
86	Identification of AML/MDS Drug Sensitization By In Vivo Chemotherapy Administration. Blood, 2020, 136, 32-33.	1.4	0
87	A sheep in wolf's clothing? Wild-type P53 disguises as mutant to promote leukemogenesis. Haematologica, 2022, , .	3.5	0